News

Mr Condella is a non-executive director of Skyepharma and Fulcrum Pharma. Mr Condella was CEO of Skyepharma from March 2006 to September 2008, president of European operations at

The US medical device operations will be overseen by Efraim Kozorovitsky, executive director of medical devices, and a four-year veteran of the company. Mr Roe has relocated from

Mr Stocks brings substantial experience and expertise to lead Calistoga Pharmaceuticals’s business and corporate development strategy, and business practices. Mr Stocks will be responsible for corporate/business development, finance

The Female Health Company’s lower-cost second generation female condom will now be available for purchase and distribution in the US. The FDA approval will also enable the US

The company has previously sold these technologies to Solos in February 2007 with the intention of Solos developing the market and revenues for the products. However, Solos’s resources

US-based pharmaceutical company Azaya Therapeutics has announced that it has been selected by the National Cancer Institute for a research collaboration to study Azaya’s lead cancer therapy, ATI-1123.

INT131-007 is a 24 week, high dose active comparator (45mg Actos) and placebo controlled study of INT131 at four doses in poorly controlled type 2 diabetics. According to

Through this validation study, AMDL and Mayo Clinic will perform clinical diagnostic testing to compare AMDL’s DR-70 (FDP) cancer test with a newly developed, next generation test. The

Mount Sinai School of Medicine has been added as a center for the Phase II study because of its reputation in dermatological research. It is anticipated that the